ConductScience.org, home

Paper36795255

Neoadjuvant Therapy with Immune Checkpoint Inhibitors in Gastric Cancer: A Systematic Review and Meta-Analysis.

Li S and 8 others. Ann Surg Oncol, 2023. Cited by 32 papers, by iCite.

Cite this record

ConductScience Library. Neoadjuvant Therapy with Immune Checkpoint Inhibitors in Gastric Cancer: A Systematic Review and Meta-Analysis. Papers, record 36795255. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36795255

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Neoadjuvant Therapy with Immune Checkpoint Inhibitors in Gastric Cancer: A Systematic Review and Meta-Analysis.
PubMed
Journal
Ann Surg Oncol
PubMed
Year
2023
PubMed
Publication types
Meta-Analysis, Systematic Review, Journal Article
PubMed
Citations, by iCite
32
iCite
Relative citation ratio, by iCite
2.68
iCite
Revised in PubMed
2023-05-15
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Li SSong
2Xu QQian
3Dai XXin
4Zhang XXue
5Huang MMiao
6Huang KKai
7Shi DDuanbo
8Wang JJian
9Liu LLianhttps://orcid.org/0000-0001-5868-4482

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Stomach NeoplasmsMajor topic
Neoplasms, Second PrimaryMajor topic
Humans
Neoadjuvant Therapy
Immune Checkpoint Inhibitors
B7-H1 Antigen
Prospective Studies
Multicenter Studies as Topic

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
82173305National Natural Science Foundation of ChinaPubMed
ZR2017MH005Natural Science Foundation of Shandong ProvincePubMed

Source PubMed

Download CSV of grants

References24

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133538338Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.CA Cancer J Clin2021https://conductscience.org/library/papers/33538338PubMed
228895113Validation of the 8th Edition of the AJCC TNM Staging System for Gastric Cancer using the National Cancer Database.Ann Surg Oncol2017https://conductscience.org/library/papers/28895113PubMed
332861308Gastric cancer.Lancet2020https://conductscience.org/library/papers/32861308PubMed
416822992Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.N Engl J Med2006https://conductscience.org/library/papers/16822992PubMed
521444866Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.J Clin Oncol2011https://conductscience.org/library/papers/21444866PubMed
630982686
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Lancet2019https://conductscience.org/library/papers/30982686PubMed
733353828Prognostic value of tumor regression grade following the administration of neoadjuvant chemotherapy as treatment for gastric/gastroesophageal adenocarcinoma: A meta-analysis of 14 published studies.Eur J Surg Oncol2021https://conductscience.org/library/papers/33353828PubMed
822395984Surgical complications in gastric cancer patients preoperatively treated with chemotherapy: their risk factors and clinical relevance.Ann Surg Oncol2012https://conductscience.org/library/papers/22395984PubMed
929543932Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.JAMA Oncol2018https://conductscience.org/library/papers/29543932PubMed
1028993052
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet2017https://conductscience.org/library/papers/28993052PubMed
1134102137
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Lancet2021https://conductscience.org/library/papers/34102137PubMed
1229658848Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.N Engl J Med2018https://conductscience.org/library/papers/29658848PubMed
1330297909Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.Nat Med2018https://conductscience.org/library/papers/30297909PubMed
1427663893Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease.Cancer Discov2016https://conductscience.org/library/papers/27663893PubMed
1530297911Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.Nat Med2018https://conductscience.org/library/papers/30297911PubMed
1612956787Methodological index for non-randomized studies (minors): development and validation of a new instrument.ANZ J Surg2003https://conductscience.org/library/papers/12956787PubMed
173802833Meta-analysis in clinical trials.Control Clin Trials1986https://conductscience.org/library/papers/3802833PubMed
1812958120Measuring inconsistency in meta-analyses.BMJ2003https://conductscience.org/library/papers/12958120PubMed
1933718040Neoadjuvant programmed cell death protein 1 inhibitors combined with chemotherapy in resectable non-small cell lung cancer: an open-label, multicenter, single-arm study.Transl Lung Cancer Res2021https://conductscience.org/library/papers/33718040PubMed
2029880231Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.Lancet2018https://conductscience.org/library/papers/29880231PubMed

See all 24 referencesDownload CSV of references

Cited by27

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 32 citations.

PMIDTitleJournalYearIn PapersSource
42857192Impact of immune checkpoint inhibitors as neoadjuvant/perioperative therapy for locally advanced resectable gastric/gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis.Front Immunol2026https://conductscience.org/library/papers/42857192PubMed
42846330Re-evaluation of lymph node dissection and surgical strategy for locally advanced gastric cancer in the era of neoadjuvant immunotherapy: a narrative review.Front Oncol2026https://conductscience.org/library/papers/42846330PubMed
42459699Tertiary lymphoid structures as biomarkers and therapeutic targets in neoadjuvant cancer immunotherapy.Front Immunol2026https://conductscience.org/library/papers/42459699PubMed
42305456The research progress of gastric cancer vaccines: a narrative review.Transl Cancer Res2026https://conductscience.org/library/papers/42305456PubMed
41924604
Efficacy and safety of perioperative immune checkpoint inhibitors combined with chemotherapy versus chemotherapy alone for locally advanced gastric or gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis of randomized phase III trials.
Front Oncol2026https://conductscience.org/library/papers/41924604PubMed
41924230
A Real-Time Online Nomogram Integrating Systemic Inflammatory Response Index and Lactate Dehydrogenase to Predict Pathological Response in Gastric Cancer Patients Receiving Neoadjuvant Chemoimmunotherapy.
Cancer Manag Res2026https://conductscience.org/library/papers/41924230PubMed
41876949Neoadjuvant Therapy for Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma: Current Status, Challenges, and Future Perspectives.Cancer Med2026https://conductscience.org/library/papers/41876949PubMed
41626148Prediction of neoadjuvant therapy efficacy in gastric cancer: the interplay between biomarkers and radiomics and its potential for clinical translation.Front Oncol2025https://conductscience.org/library/papers/41626148PubMed
41607794Survival and multi-omics analysis of immunotherapy-based conversion treatment for initially unresectable gastric cancer.Front Immunol2025https://conductscience.org/library/papers/41607794PubMed
41551523Artificial intelligence and machine learning-driven advancements in gastrointestinal cancer: Paving the way for precision medicine.World J Gastroenterol2026https://conductscience.org/library/papers/41551523PubMed
41317985Radiation Therapy for Gastric Cancer: An ASTRO Clinical Practice Guideline.Pract Radiat Oncol2026https://conductscience.org/library/papers/41317985PubMed
41184754Therapeutic efficacy of multiple neoadjuvant regimens involving targeted therapy, immunotherapy and chemotherapy in gastric cancer: a systematic review and meta-analysis.BMC Cancer2025https://conductscience.org/library/papers/41184754PubMed
41114345Pathologic complete response of advanced hepatoid adenocarcinoma of the stomach following immuno-chemotherapy and conversion surgery: a rare case report and review of the literature.Front Oncol2025https://conductscience.org/library/papers/41114345PubMed
40851424
Human Epidermal Growth Factor Receptor 2 [HER-2/neu] Amplification and Microsatellite Stable Status in Gastric and Gastroesophageal Adenocarcinoma: Assessing Frequency and Prognostic Implications at the Cancer Institute of Iran.
Cancer Rep (Hoboken)2025https://conductscience.org/library/papers/40851424PubMed
40591222Escalation and de-escalation in surgery for gastric cancer.Int J Clin Oncol2025https://conductscience.org/library/papers/40591222PubMed
40119433The artificial intelligence revolution in gastric cancer management: clinical applications.Cancer Cell Int2025https://conductscience.org/library/papers/40119433PubMed
39967656Neoadjuvant chemotherapy combined with antiangiogenic therapy and immune checkpoint inhibitors for the treatment of locally advanced gastric cancer: a real - world retrospective cohort study.Front Immunol2025https://conductscience.org/library/papers/39967656PubMed
39871229Impact of Helicobacter pylori infection on neoadjuvant chemotherapy in locally advanced gastric cancer: a retrospective analysis.BMC Cancer2025https://conductscience.org/library/papers/39871229PubMed
39675826Chemotherapy combined with immunotherapy in patients with gastric cancer: protocol for a systematic review.BMJ Open2024https://conductscience.org/library/papers/39675826PubMed
39050856Prognostic value of inflammatory markers NLR, PLR, and LMR in gastric cancer patients treated with immune checkpoint inhibitors: a meta-analysis and systematic review.Front Immunol2024https://conductscience.org/library/papers/39050856PubMed

See all 27 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36795255

GET https://conductscience.org/api/papers/v1/36795255/references?page=2